Core Points - The revised "Beijing Non-Motor Vehicle Management Regulations" will be implemented on May 1, 2026, mandating helmet use for electric bicycle riders and issuing special license plates for those used in internet rental or delivery services [1][2] Group 1: Regulations on Electric Bicycles - Electric bicycles and their components must meet national standards and undergo mandatory product certification to ensure safety [2] - A safety assessment system is established for electric bicycle batteries, requiring those over five years old to undergo evaluation [2] - Electric bicycles must be registered to obtain a driving license and license plate, which are valid for ten years with an option for renewal [2] Group 2: Safety and Conduct Regulations - The age limit for carrying minors on electric bicycles has been raised from under 12 to under 16 years [4] - Strict prohibitions are placed on dangerous driving behaviors, including speeding, driving under the influence, and using mobile devices while riding [4][5] - The regulations emphasize the importance of wearing certified helmets and outline penalties for non-compliance [4] Group 3: Management of Modifications and Violations - Any unauthorized modifications or installations on electric bicycles are strictly prohibited, with penalties for violations [5] - Traffic violations recorded by monitoring equipment will require the owner to address them within a specified timeframe, or face penalties including license suspension [5] Group 4: Infrastructure and Charging Facilities - The regulations mandate the construction of adequate parking and charging facilities for electric bicycles, integrated into urban planning [7] - New public buildings must include non-motor vehicle parking facilities, and existing facilities must be upgraded to meet demand [7] - The transport of electric bicycle batteries into residential buildings is prohibited to enhance safety [6][7]

Summary of Jasper Therapeutics (JSPR) Update / Briefing July 07, 2025 Company Overview - **Company**: Jasper Therapeutics (JSPR) - **Focus**: Development of therapies for chronic spontaneous urticaria (CSU) using the drug vaprolimab Key Points Industry and Company Context - The conference call was focused on updated data from the BEACON trial and initial data from the open label extension study evaluating vaprolimab in patients with CSU [4][20] Core Findings from the BEACON Trial - **Efficacy**: - A greater than 25 drop in UAS7 (Urticaria Activity Score over 7 days) was observed in the 240 mg and 360 mg single dose cohorts, with 78% complete response and 89% well-controlled disease by week four [4][21] - In the open label extension study, 73% of patients achieved complete response and 82% well-controlled disease at the 12-week assessment with a mean reduction in UAS7 scores of greater than 25 points [17][22] - **Safety Profile**: - Vaprolimab demonstrated a favorable safety profile with no dose-limiting toxicities reported. Treatment emergent adverse events were similar in both active and placebo groups [13][22] - Mild transient adverse events were observed, including taste changes and neutrophil count reductions, but these were self-resolving and did not lead to discontinuations [14][15] Issues Identified - **Confounding Results**: - Two cohorts (240 mg Q8 weeks and 240 mg followed by 180 mg Q8 weeks) showed confounded results due to an issue with a specific drug product lot (lot A34954), which resulted in lower than expected drops in mean tryptase levels and no discernible effect on UAS7 in 10 out of 10 patients dosed with this lot [5][12] - An investigation into the affected lot is ongoing, with results expected in the coming weeks [6][20] - **Next Steps**: - Additional 10 to 12 patients will be enrolled in the affected cohorts to ensure a robust data set for the Phase IIb CSU study expected to commence mid-2026 [6][20] Financial and Operational Insights - **Cash Runway**: - Current guidance into the fourth quarter remains unchanged, but the company is evaluating its cost structure and may need to raise additional capital to extend its runway [54] - **Regulatory Communication**: - The company is in communication with the FDA regarding the lot issue, but there are no safety concerns associated with the affected lot [48][41] Additional Observations - **Durability of Responses**: - The data suggests that the depth of triptase reduction correlates with the depth of UAS7 reductions, indicating a potential for durable effects with the 180 mg dosing regimen [55] - **Patient Management**: - Patients who received the inactive dose from the compromised lot will be transitioned to a new drug product that has demonstrated efficacy in other cohorts [20][48] Conclusion - Jasper Therapeutics is optimistic about the potential of vaprolimab as a differentiated therapeutic option for CSU, despite the setback from the compromised drug lot. The company is taking proactive steps to address the issue and continue its clinical development program.